Brokerages forecast that Citius Pharmaceuticals Inc (NASDAQ:CTXR) will post ($0.12) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Citius Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.09) and the lowest estimate coming in at ($0.14). Citius Pharmaceuticals reported earnings of ($0.18) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 33.3%. The business is expected to report its next quarterly earnings report on Tuesday, December 10th.
On average, analysts expect that Citius Pharmaceuticals will report full year earnings of ($0.61) per share for the current fiscal year, with EPS estimates ranging from ($0.61) to ($0.60). For the next year, analysts anticipate that the firm will post earnings of ($0.41) per share, with EPS estimates ranging from ($0.43) to ($0.38). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Citius Pharmaceuticals.
A number of equities research analysts have recently commented on CTXR shares. Dawson James started coverage on Citius Pharmaceuticals in a research report on Friday, September 6th. They set a “buy” rating and a $7.00 target price on the stock. Zacks Investment Research upgraded Citius Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 22nd.
Shares of NASDAQ:CTXR traded down $0.02 during trading on Monday, reaching $0.44. 330,186 shares of the company’s stock traded hands, compared to its average volume of 152,428. Citius Pharmaceuticals has a fifty-two week low of $0.42 and a fifty-two week high of $1.79. The firm has a market cap of $9.71 million, a PE ratio of -0.38 and a beta of 0.50. The company has a 50-day simple moving average of $0.52 and a 200-day simple moving average of $0.92.
In related news, major shareholder Leonard L. Mazur purchased 2,234,700 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average cost of $0.90 per share, with a total value of $2,011,230.00. Also, CEO Myron Z. Holubiak purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 25th. The stock was bought at an average cost of $6.02 per share, for a total transaction of $30,100.00. Insiders purchased a total of 2,798,297 shares of company stock worth $2,544,067 over the last ninety days. 58.52% of the stock is currently owned by corporate insiders.
An institutional investor recently raised its position in Citius Pharmaceuticals stock. Vanguard Group Inc. boosted its stake in Citius Pharmaceuticals Inc (NASDAQ:CTXR) by 308.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 453,156 shares of the company’s stock after buying an additional 342,180 shares during the quarter. Vanguard Group Inc. owned approximately 2.05% of Citius Pharmaceuticals worth $444,000 at the end of the most recent reporting period. 16.51% of the stock is currently owned by hedge funds and other institutional investors.
Citius Pharmaceuticals Company Profile
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.
Recommended Story: What is Compound Annual Growth Rate (CAGR)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.